novavax vaccine - Search News

News

Novavax scores narrower Covid vaccine approval

CNBC on MSN · 2d

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's Covid-19 vaccine after more than a month of delay b

Infectious Disease Advisor · 1d

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

FDA Approves Novavax COVID Vaccine With Restricted Use

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from COVID can also get the shot.

FDA gives Covid vaccine manufacturers instructions for next fall’s shot

The notice came shortly after an advisory panel meeting at which members debated the pros and cons of asking manufacturers to ...

16h

Trump’s FDA just changed COVID vaccine rules for 2025 — will you still qualify for boosters under the new guidelines?

FDA COVID vaccine update is stirring major public attention as a new policy limits fall COVID-19 booster shots to seniors and ...

3d

JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results